Can Vaccines Be Delivered via the Lungs Instead of by Injection?

Can Vaccines Be Delivered via the Lungs Instead of by Injection?

15 October 2012 Mary Ann Liebert, Inc., Publishers

New Rochelle, NY, October 15, 2012—In addition to the obvious benefit of eliminating the need for an injection, new vaccine delivery methods via the lungs offer particular advantages for protecting against infectious agents that enter the body through the respiratory track. A comprehensive review article that presents the current status, challenges, and opportunities of pulmonary vaccine delivery is published in Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com). The article is available free online on the Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) website.

In "Pulmonary Vaccine Delivery: A Realistic Approach? (http://online.liebertpub.com/doi/full/10.1089/jamp.2011.0931)" Wouter Tonnis and coauthors from University of Groningen and National Institute for Public Health and the Environment (Bilthoven), The Netherlands, describe the unique physiology and immune responsiveness of the respiratory track that make pulmonary vaccine delivery such an attractive alternative to traditional injections. Although pulmonary vaccination is still a young field, with much more research needed, evidence suggests administration of a vaccine to the lungs can induce a local immune response more effectively than conventional types of vaccine delivery, in addition to stimulating antibody production throughout the body. This could be especially important for combating pathogens that cause pulmonary diseases.

"The lung is an immunologic powerhouse that remains largely unexplored. Theoretically we should be able to avoid needles and simply inhale our vaccines," says Editor-in-Chief Gerald C. Smaldone, MD, PhD, Professor and Chief, Division of Pulmonary and Critical Care Medicine at SUNY-Stony Brook.

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.